The POLLUX trial was designed for patients with relapsed myeloma who have received at least one but no more than three prior lines of therapy. These patients were randomised to receive either lenalidomide dexamethasone continuously or lenalidomide dexamethasone with daratumumab. In this meeting we presented an update of the POLLUX trial which shows that with a median follow-up of more than thirty months there is a continuous benefit in favour of daratumumab with lenalidomide dexamethasone. The median PFS has not been reached whereas median PFS for lenalidomide dexamethasone is 17.5 months. Furthermore, there is a further improvement of the complete response rate with continuous therapy and also by evaluating minimal residual disease with next generation frequency we observed that approximately 27% of the patients who were randomised to receive daratumumab with lenalidomide dexamethasone achieved MRD negativity at the level of 10-5.

What could be the impact of this research?

Definitely daratumumab with lenalidomide dexamethasone is probably the most active regimen for the treatment of patients with relapsed myeloma. It is associated with the longest ever reported PFS with an excellent tolerability profile.